M&A by sector: seven largest mergers and acquisitions in the life sciences industry

This blog is in the Top 25 M&A blogs worldwide according to Feedspot

Here, the seven largest mergers and acquisitions (M&A) transactions in the life sciences industry within the last five years are outlined, providing comprehensive details regarding their financial valuations and targeted synergies.

Pfizer Inc.'s acquisition of Seagen Inc. in 2023, valued at $43 billion, was aimed at broadening Pfizer's oncology pipeline by leveraging Seagen's expertise in innovative cancer treatments, particularly antibody-drug conjugates (ADCs). The deal's objective is to improve patient outcomes through the development of new cancer therapies.

In 2023, Amgen Inc. acquired Horizon Therapeutics for $28.3 billion to enhance its presence in the rare disease market. Horizon's reputation for treating rare autoimmune and severe inflammatory diseases complements Amgen's biologics capabilities, promising improved treatment options for patients with rare diseases.

Merck & Co Inc.'s 2023 acquisition of Prometheus Biosciences for $10.8 billion aimed to strengthen its immunology pipeline with Prometheus's precision medicine for immune-mediated diseases. The merger is anticipated to accelerate the development of targeted therapies for autoimmune diseases.

Biogen Inc.'s 2023 acquisition of Reata Pharmaceuticals for $7.3 billion aimed at expanding its neurology and rare disease portfolio. Reata's focus on severe neurological and rare diseases is expected to address unmet medical needs and enhance Biogen's capabilities in these areas.

In 2022, Amgen Inc. acquired Horizon Therapeutics for $27.8 billion to bolster its portfolio in rare diseases and immunology. The synergies between Amgen's biologics capabilities and Horizon's therapies are expected to enhance treatment options for patients with rare diseases.

Pfizer Inc.'s 2022 acquisition of Biohaven Pharmaceuticals for $11.6 billion aimed to expand its neurology portfolio with Biohaven's treatments for migraine and other neurological disorders. The integration of Biohaven's innovative treatments with Pfizer's portfolio is expected to enhance treatment options for patients with neurological disorders.

AstraZeneca's $39 billion acquisition of Alexion Pharmaceuticals in 2020 aimed to strengthen its presence in the rare disease market with Alexion's treatments for rare and ultra-rare diseases. The deal is expected to enhance treatment options for patients with rare diseases by combining AstraZeneca's global reach and scientific expertise with Alexion's innovative therapies.

These transactions underscore the strategic maneuvers of major pharmaceutical firms to expand their portfolios, enhance their capabilities, and address unmet medical needs across various therapeutic domains.

Like my thoughts? READ MY NEW BOOK
ORDER AT AMAZON
ORDER IN GERMANY